# Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

> **NCT00854945** · PHASE1,PHASE2 · COMPLETED · sponsor: **Traws Pharma, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** ON 01910.Na

## Key facts

- **NCT ID:** NCT00854945
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2013-09
- **Final completion:** 2014-02
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854945, "Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00854945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*